Comparison of whole-exome, whole-transcriptome genomic profiling and targeted sequencing with 50-gene panels in advanced solid tumors
The value of genomic profiling in advanced solid tumors using whole-exome, whole-transcriptome sequencing (WES/WTS) in comparison to 50-gene panels is evaluated to identify potential matched therapies, thereby informing clinical decision-making and potentially improving outcomes for more patients.